Pharmacology & Therapeutics

Article	Citations
WITHDRAWN: 17th International conference on bioactive lipids in cancer, inflammation and related diseases virtual special issue	415
Measuring brain docosahexaenoic acid turnover as a marker of metabolic consumption	302
Editorial Board	296
HIV-associated neurotoxicity and cognitive decline: Therapeutic implications	254
Unlocking the power of affibody conjugated radioactive metallopharmaceuticals for targeted cancer diagnosis and therapy	250
Non-canonical G protein signaling	235
Adenosine receptor signalling as a driver of pulmonary fibrosis	205
Inflammation, lipids, and pain in vulvar disease	204
Collateral lethality: A unique type of synthetic lethality in cancers	199
Endothelial dysfunction as a complication of anti-cancer therapy	173
Potential neonatal toxicity of new psychoactive substances	169
The role of macrophages in asthma-related fibrosis and remodelling	167
Unfolded protein responses: Dynamic machinery in wound healing	162
Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis	161
Exploiting the obesity-associated immune microenvironment for cancer therapeutics	149
New therapeutic horizons for plasma phospholipid transfer protein (PLTP): Targeting endotoxemia, infection and sepsis	141
Matrikines in the skin: Origin, effects, and therapeutic potential	130
In cancer, all roads lead to NADPH	128
Sulfoconjugation of protein peptides and glycoproteins in physiology and diseases	125
Regulatory lipid vicinal diols counteract the biological activity of epoxy fatty acids and can act as biomarkers and mechanisms for disease progression	125
Sleep apnea and pulmonary hypertension: A riddle waiting to be solved	122
Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches	122
Imaging neuroinflammation with TSPO: A new perspective on the cellular sources and subcellular localization	121
Boron in cancer therapeutics: An overview	115
Pharmacological modulation of respiratory control: Ampakines as a therapeutic strategy	113

Contribution of non-selective membrane channels and receptors in epilepsy	103
Management of drug-resistant hypertension as a heterogeneous disorder	101
Endothelial function and dysfunction: Impact of sodium-glucose cotransporter 2 inhibitors	100
Myeloid cells in the era of cancer immunotherapy: Top 3 unanswered questions	97
Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics	95
Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases	94
Targeting the p38α pathway in chronic inflammatory diseases: Could activation, not inhibition, be the appropriate therapeutic strategy?	92
The phospholipase A2 superfamily as a central hub of bioactive lipids and beyond	92
Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets	90
Dysregulation of metabolic pathways in pulmonary fibrosis	90
TLR4 biased small molecule modulators	87
TAAR1 as an emerging target for the treatment of psychiatric disorders	87
Cell-based therapies for vascular regeneration: Past, present and future	87
Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance	86
Is the peroxisome proliferator-activated receptor gamma a putative target for epilepsy treatment? Current evidence and future perspectives	83
Bispecific antibodies for the treatment of neuroblastoma	82
Natural products that alleviate depression: The putative role of autophagy	81
Corrigendum to “The role of CD71+ erythroid cells in the regulation of the immune response” [Pharmacology & Therapeutics 228 (2021) 107927]	80
Review: Sex-related differences in the treatment of cardiac arrhythmia	80
Editorial Board	80
PGRMC1: An enigmatic heme-binding protein	78
Wnt signaling: A prospective therapeutic target for chronic pain	77
Emerging role of ferroptosis in breast cancer: New dawn for overcoming tumor progression	73
Pharmacological treatment of cardiogenic shock – A state of the art review	73
Interactions between NSAIDs, opioids and the gut microbiota - Future perspectives in the management of inflammation and pain	70
Therapeutic implications of impaired nuclear receptor function and dysregulated metabolism in Wilson's disease	69
The pathomimetic oAβ25–35 model of Alzheimer's disease: Potential for screening of new therapeutic agents	69
G protein-coupled receptor-effector macromolecular membrane assemblies (GEMMAs)	69
Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: Efficacies and mechanisms	68
Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance	68
Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases	67
Recent advances in metabolism and toxicity of tyrosine kinase inhibitors	67
A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy	67
Targeting Sirtuin1 to treat aging-related tissue fibrosis: From prevention to therapy	67
The role of microglia heterogeneity in synaptic plasticity and brain disorders: Will sequencing shed light on the discovery of new therapeutic targets?	66
Stabilizing the neural barrier – A novel approach in pain therapy	66
Signal transduction in primary cilia – analyzing and manipulating GPCR and second messenger signaling	65
DNA methylation in cell plasticity and malignant transformation in liver diseases	65
CircRNAs as upstream regulators of miRNA//HMGA2 axis in human cancer	65
Autophagy inhibitors for cancer therapy: Small molecules and nanomedicines	64
Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response	64
HDL-based therapeutics: A promising frontier in combating viral and bacterial infections	63
Advances in pathogenesis and therapeutic strategies for osteoporosis	63
Editorial Board	62
Optimizing drug therapies in cardiac amyloidosis	61
Extracellular vesicles in cardiovascular disease: Biological functions and therapeutic implications	60
The therapeutic potential of Nrf2 inducers in chronic pain: Evidence from preclinical studies	60
Chemical diversity, traditional uses, and bioactivities of Rosa roxburghii Tratt: A comprehensive review	59
Myeloperoxidase: Growing importance in cancer pathogenesis and potential drug target	58
MAS-related G protein-coupled receptors X (MRGPRX): Orphan GPCRs with potential as targets for future drugs	57

Drug repurposing for COVID-19: Approaches, challenges and promising candidates	56
Recent advances in riboflavin transporter RFVT and its genetic disease	56
Therapeutic targeting of DNA methylation alterations in cancer	55
The role of drug-metabolizing enzymes in synthetic lethality of cancer	54
17β-hydroxysteroid dehydrogenases in the progression of nonalcoholic fatty liver disease	54
Neuromuscular and cardiac organoids and assembloids: Advanced platforms for drug testing	54
In vitro functional assays as a tool to study new synthetic opioids at the μ-opioid receptor: Potential, pitfalls and progress	53
Noncoding RNA circuitry in melanoma onset, plasticity, and therapeutic response	53
Endothelial shear stress signal transduction and atherogenesis: From mechanisms to therapeutics	53
Regulation of feeding and therapeutic application of bioactive peptides	53
Emerging roles of RNA ac4C modification and NAT10 in mammalian development and human diseases	53
Bridging the gap: The endocannabinoid system as a functional fulcrum for benzodiazepines in a novel frontier of anxiety pharmacotherapy	52
MicroRNAs in drug addiction: Current status and future perspectives	51
Editorial Board	51
Editorial Board	51
Cannabinoid receptor 1 ligands: Biased signaling mechanisms driving functionally selective drug discovery	50
Pathological changes in GPCR signal organisation: Opportunities for targeted therapies for triple negative breast cancer	50
Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation	49
Pharmacological potential of cyclic nucleotide signaling in immunity	49
Emerging methods for and novel insights gained by absolute quantification of mitochondrial DNA copy number and its clinical applications	49
CDNF and ER stress: Pharmacology and therapeutic possibilities	48
The emerging science of Glioception: Contribution of glia in sensing, transduction, circuit integration of interoception	48
Lactate acidosis and simultaneous recruitment of TGF-β leads to alter plasticity of hypoxic cancer cells in tumor microenvironment	47
Consideration of albumin-mediated hepatic uptake for highly protein-bound anionic drugs: Bridging the gap of hepatic uptake clearance between in vitro and in vivo	47
Musculoskeletal crosstalk in chronic obstructive pulmonary disease and comorbidities: Emerging roles and therapeutic potentials	46
Update on treatment of abdominal pain in irritable bowel syndrome: A narrative review	46
Translating biased agonists from molecules to medications: Serotonin 5-HT1A receptor functional selectivity for CNS disorders	46
Immunotherapy for hepatocellular carcinoma: Recent advances and future targets	46
Organic anion transporters in remote sensing and organ crosstalk	45
Resolving inflammation by TAM receptor activation	45
Editorial Board	45
G protein-coupled estrogen receptor biased signaling in health and disease	45
The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications	45
Integrins in cancer: Emerging mechanisms and therapeutic opportunities	45
Exploring the landscape of post-translational modification in drug discovery	45
Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination	44
The role and participation of immune cells in the endometrial tumor microenvironment	44
Pharmacological interventions for intraplaque neovascularization in atherosclerosis	44
Biased agonism in drug discovery: Is there a future for biased 5-HT1A receptor agonists in the treatment of neuropsychiatric diseases?	44
The tissue-specific transcriptional landscape underlines the involvement of endothelial cells in health and disease	44
The (neuro)inflammatory system in anxiety disorders and PTSD: Potential treatment targets	44
Targeting cancer-associated fibroblasts: Challenges, opportunities and future directions	44
Modulation of hyaluronan signaling as a therapeutic target in human disease	44
Neurobiological mechanisms of botulinum neurotoxin-induced analgesia for neuropathic pain	44
Molecular mechanisms of ferroptosis and their involvement in brain diseases	43
Annexin A1 in neurological disorders: Neuroprotection and glial modulation	43
Editorial Board	43
Platelet lipid metabolism in vascular thrombo-inflammation	42
Understanding the molecular bridges between the drugs and immune cell	42
Development and clinical translation of P2X7 receptor antagonists: A potential therapeutic target in coronary artery disease?	41
Attributes novel drug candidate: Constitutive GPCR signal bias mediated by purinergic receptors	41
Following the design path of isoform-selective Hsp90 inhibitors: Small differences, great opportunities	41
The role of osteoprotegerin (OPG) in fibrosis: its potential as a biomarker and/or biological target for the treatment of fibrotic diseases	41
Potential targeting of the tumor microenvironment to improve cancer virotherapy	40
Phosphorylation of nuclear receptors: Novelty and therapeutic implications	39
From bench to clinic: Emerging therapies for corneal scarring	38
Experimental considerations for the assessment of in vivo and in vitro opioid pharmacology	38
Editorial Board	38
Advances in anticancer alkaloid-derived metallo-chemotherapeutic agents in the last decade: Mechanism of action and future prospects	38
Early life adversities, psychopathologies and novel pharmacological strategies	38
Advances in the pathophysiology of atopic dermatitis revealed by novel therapeutics and clinical trials	37
Signaling pathways in brain ischemia: Mechanisms and therapeutic implications	37
Targeting the Semaphorin3E-plexinD1 complex in allergic asthma	37
Immune cells and their derived microRNA-enriched extracellular vesicles in nonalcoholic fatty liver diseases: Novel therapeutic targets	36
Roles of NLRC4 inflammasome in neurological disorders: Mechanisms, implications, and therapeutic potential	36
Prolactin and pain of endometriosis	36
The essential role of docosahexaenoic acid and its derivatives for retinal integrity	36
Therapeutic antibodies – natural and pathological barriers and strategies to overcome them	35
Post-COVID pulmonary sequelae: Mechanisms and potential targets to reduce persistent fibrosis	35
Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy	35
Nanotechnology and nano-sized tools: Newer approaches to circumvent oncolytic adenovirus limitations	35
Resolution of inflammation: An organizing principle in biology and medicine	34
Modulating glucocorticoid receptor actions in physiology and pathology: Insights from coregulators	34
Editorial Board	34
Plant-derived nanovesicles and therapeutic application	34
Editorial Board	34
Role of phosphodiesterase 1 in the pathophysiology of diseases and potential therapeutic opportunities	34
The antidepressant actions of ketamine and its enantiomers	34
Bile acids and neurological disease	33
Distinct mechanisms underlying therapeutic potentials of CD20 in neurological and neuromuscular disease	33

Protoporphyrin IX-induced phototoxicity: Mechanisms and therapeutics	33
Multitasking bamboo leaf-derived compounds in prevention of infectious, inflammatory, atherosclerotic, metabolic, and neuropsychiatric diseases	33
GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?	32
Chloride channels in the lung: Challenges and perspectives for viral infections, pulmonary arterial hypertension, and cystic fibrosis	32
Retina-directed gene therapy: Achievements and remaining challenges	31
Icosapent ethyl in cardiovascular prevention: Resolution of inflammation through the eicosapentaenoic acid - resolvin E1 - ChemR23 axis	31
Gene and stem cell therapy for inherited cardiac arrhythmias	31
Endotheliopathy in the metabolic syndrome: Mechanisms and clinical implications	31
Benzamide derivative radiotracers targeting melanin for melanoma imaging and therapy: Preclinical/clinical development and combination with other treatments	31
Biased signaling in drug discovery and precision medicine	31
Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics	30
Current state and novel outlook on prevention and treatment of rising antibiotic resistance in urinary tract infections	30
Editorial Board	30
Post-translational modifications of histone and non-histone proteins in epigenetic regulation and translational applications in alcohol-associated liver disease: Challenges and research opportunities	30
Treatment of overdose in the synthetic opioid era	30
Anti-cancer activity of sustained release capsaicin formulations	30
Gut dysbiosis, defective autophagy and altered immune responses in neurodegenerative diseases: Tales of a vicious cycle	30
Spotlight on plasticity-related genes: Current insights in health and disease	30